Painful bruising syndrome (also known as "autoerythrocyte sensitization", "Gardner–Diamond syndrome", and "psychogenic purpura") is an idiopathic trauma-induced condition seen in young to middle-aged women who sometimes manifest personality disorders. : 829   It is characterized by a distinctive localized purpuric reaction occurring primarily on the legs, face and trunk, with recurring painful ecchymoses variably accompanied by syncope, nausea, vomiting, gastrointestinal and intracranial bleeding.Patients with this condition can experience frequent painful bruising around joints and muscles. Because of the rarity of the disorder, there are few methods of support in place for patients.Many patients are labelled with the stigma of having a psychological condition without this having a specifically proven link. There have been cases of painful bruising syndrome reported where there are no additional psychological disorders. This has been known to be put into remission with chemotherapy. It was characterized in 1955 by Frank Gardner and Louis Diamond.Patient may present with a history of intermittent purpura mostly precipitated by stress. See also
List of cutaneous conditions

References
Further reading
Panconesi, E., & Hautmann, G. (1995). Stress, Stigmatization and Psychosomatic Purpuras. International Angiology 14: 130–137. Yuecel, B., Kiziltan, E., & Aktan, M. (2000). Dissociative Identity Disorder Presenting With Psychogenic Purpura. Psychosomatics 41: 279–281. == External links ==
Acquisition attempts
In early 2014, Endo sought to acquire NuPathe, a speciality pharmaceutical developer, for $105 million. However, Teva prevailed in this acquisition with a substantially higher bid. Bankruptcy
In 2022, Endos stock fell below $1 as the company faced restructuring of its $8 billion of debt. On August 17, 2022 Endo International Plc filed for Chapter 11 bankruptcy protection after reaching a $6 billion deal with some of its creditors. Opioids
Endo is one of the companies named in lawsuits by the states of Ohio, Missouri and Mississippi as responsible for the US opioid epidemic. Its 10-K statement indicates that a majority of the companys US revenue in 2016 was derived from the sale of prescription pain killers, predominantly opioids.On June 8, 2017, the U.S. Food and Drug Administration (FDA) released a press statement in which it announced that it requested Endo to withdraw its opioid drug, oxymorphone hydrochloride (Opana ER), from the market. Opana has been linked to outbreaks of HIV, hepatitis C and serious blood disorders. It was the first time that the FDA had "taken steps to remove a currently marketed opioid pain medication from sale due to the public health consequences of abuse. "In 2021, New York Attorney General Letitia James filed a lawsuit against Endo and several other opioid manufacturers for their alleged contribution to the opioid epidemic in New York. See also
Opioid epidemic
Corporate tax inversions
Ireland as a tax haven

References
External links
Official website